Vimarsana
Biggest News Aggregation in the World

Page 2 - Discovery Engine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Discovery Engine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Discovery Engine Today - Breaking & Trending Today

Why Pinterest Influences App Engagement - Vimarsana News

Why Pinterest Influences App Engagement

Have you ever wondered why Pinterest has such a magical touch, not just on your creative impulses, but also in the plethora of other apps around you? It’s more than just a visual paradise of pins and boards; it has a profound impact on the engagement levels of various apps Here are some interesting facts […]

Invaio Sciences announces acquisition of Peptyde Bio - Vimarsana News

Invaio Sciences announces acquisition of Peptyde Bio

Invaio Sciences has acquired Peptyde Bio to bring an established platform and IP portfolio enabling Invaio to speed up the design and discovery of peptides

Jefferies Upgrades Arvinas to Buy From Hold, Raises Price Target to $40 From $32 - Vimarsana News

Jefferies Upgrades Arvinas to Buy From Hold, Raises Price Target to $40 From $32

-- Arvinas has an average buy rating and a price target range of $20 to $110, according to analysts polled by Capital IQ. Price: 30.39, Change: +7.22, Percent Change: +31.14 ...

Related Topics:
Arvinas IncDiscovery Engine
Arvinas Announces Oversubscribed $350 Million Private Placement - Vimarsana News

Arvinas Announces Oversubscribed $350 Million Private Placement

NEW HAVEN, Conn., Nov. 27, 2023 -- Arvinas, Inc. , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered...

Arvinas Announces Oversubscribed $350 Million Private Placement - Vimarsana News

Arvinas Announces Oversubscribed $350 Million Private Placement

NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced